Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CLYM vs IBO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IBO Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 5–4 Matrix Metrics)

IBO Overall Winner 6-Pillar Tally: CLYM 0 – 4 IBO (2 Tie) Matrix Metrics: CLYM 4 – 5 IBO

As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Climb Bio, Inc. (CLYM) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CLYM carries a Unified Composite Score of 41.9/100 (SELL) at $9.94 (N/M Forward P/E, 0.0% operating margin), whereas IBO carries 36.8/100 (SELL) at $4.91 (N/M Forward P/E, -12621.0% operating margin).

  • Composite vs. Pillar Nuance: While CLYM currently prints a higher short-term Unified Composite Score (41.9/100 SELL vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. 0.0% operating margin) and revenue trajectory (+16.7% vs. +0.0% YoY).
  • Defensive Composite Rating Caution: Although IBO compares more favorably head-to-head, both CLYM (41.9/100 SELL) and IBO (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CLYM vs IBO
CLYM NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.94
-4.05% 1D
Market Cap $608.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.50β · 114% Vol
Unified Composite Score
41.9 / 100 SELL
Tech 38.0 Fund 42.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.5 · SMA20: $10.28 · SMA50: $11.47
IBO NYSE American Head-to-Head Winner
Impact BioMedical, Inc.
Pharmaceutical Preparations
$4.91
-4.47% 1D
Market Cap $44.4M
TTM Revenue $2.6M
Forward P/E N/M
Beta / 30D Vol -6.72β · 120% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 15.0 Fund 32.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (71.0% over 20 days), RSI 62
RSI-14: 62.4 · SMA20: $4.12 · SMA50: $3.52

6-Pillar Scorecard Institutional Category Breakdown (CLYM 0 – 4 IBO)

Columns: Metric · CLYM · IBO
1. Valuation Multiples IBO
Forward P/E N/M N/M
Trailing P/E N/M 0.4x
PEG Ratio N/M N/M
EV / Revenue N/M 17.4x
2. Growth & Scale IBO
Revenue Growth (YoY) +0.0% +16.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $2.6M
Market Cap $608.5M $44.4M
3. Profitability & Quality IBO
Gross Margin N/A N/A
Operating Margin 0.0% -12621.0%
Net Profit Margin 0.0% 4247.4%
Return on Equity (ROE) -29.3% 71.2%
4. Balance Sheet & Cash Flow IBO
Cash Generation (TTM) N/A -$284M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.95 Book/Sh · -29.3% ROE $1.18 Book/Sh · 71.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CLYM (4) vs IBO (5)
Institutional Metric CLYM IBO Criterion Row Edge
Market Capitalization
Scale
$608.5M $44.4M Larger Scale CLYM
Trailing P/E Ratio
Valuation
N/M 0.4x Lower Multiple IBO
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +16.7% Higher Growth IBO
Operating Margin (TTM)
Profitability
0.0% -12621.0% Higher Margin CLYM
Net Profit Margin
Profitability
0.0% 4247.4% Higher Margin IBO
Return on Equity (ROE)
Capital Efficiency
-29.3% 71.2% Higher ROE IBO
52-Week Range Position
Momentum
50% ($2–$18) 67% ($0–$7) Stronger Trend IBO
Beta / 30D Volatility
Risk Regime
1.50β · 114% Vol -6.72β · 120% Vol Lower Realized Risk CLYM
Unified Institutional Score
Composite Signal
41.9 / 100 (SELL) 36.8 / 100 (SELL) Higher Composite CLYM
Trailing 12M Revenue (USD)
Operating Scale
N/A $2.6M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 17.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($3.95 Book/Sh · -29.3% ROE) -$284M EBITDA ($1.18 Book/Sh · 71.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IBO +81.99 pp
CLYM: +1.22% · IBO: +83.21%
3M Horizon IBO +987.52 pp
CLYM: -42.84% · IBO: +944.68%
6M Horizon IBO +811.52 pp
CLYM: +0.61% · IBO: +812.13%
1Y Horizon IBO +431.2 pp
CLYM: +431.55% · IBO: +862.75%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs IBO. Trailing 12-month operating profitability (CLYM 0.0% vs IBO -12621.0%) and valuation multiples (CLYM N/M vs IBO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CLYM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-29.3% · N/M
IBO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.6M
Gross MarginN/A
Op. Margin-12621.0%
ROE / Fwd P/E71.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CLYM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CLYM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IBO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IBO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CLYM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $608.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IBO Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $44.4M market capitalization and -12621.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CLYM vs IBO Key Questions & Quantitative Answers

As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Climb Bio, Inc. (CLYM) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CLYM carries a Unified Composite Score of 41.9/100 (SELL) at $9.94 (N/M Forward P/E, 0.0% operating margin), whereas IBO carries 36.8/100 (SELL) at $4.91 (N/M Forward P/E, -12621.0% operating margin). Composite vs. Pillar Nuance: While CLYM currently prints a higher short-term Unified Composite Score (41.9/100 SELL vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. 0.0% operating margin) and revenue trajectory (+16.7% vs. +0.0% YoY). Defensive Composite Rating Caution: Although IBO compares more favorably head-to-head, both CLYM (41.9/100 SELL) and IBO (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

IBO leads the Growth & Scale pillar: CLYM posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with IBO at +16.7% YoY revenue growth and +0.0% YoY earnings growth on $2.6M TTM revenue (N/A gross margin, -12621.0% operating margin). On trailing 12-month operating scale, CLYM generates N/A in USD-normalized revenue versus $2.6M for IBO. In operating R&D and SG&A reinvestment, CLYM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IBO.

IBO screens cheaper on headline valuation multiples. CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas IBO trades at N/M Forward P/E, 0.4x Trailing P/E, N/M PEG, and 17.4x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CLYM (-29.3% ROE) versus IBO (71.2% ROE) capital efficiency.

In options market volatility and institutional positioning, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.50β · 114% Vol realized risk). By comparison, IBO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-6.72β · 120% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.